Progress in the treatment of multiple myeloma.
Kumar
Shaji
S
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. kumar.shaji@mayo.edu
D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008558:Melphalan / Q000627:therapeutic use*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009101:Multiple Myeloma / Q000188:drug therapy*; D011239:Prednisolone / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*
D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D013792:Thalidomide; D011239:Prednisolone; D008558:Melphalan